Bibliography

ADC

More information about our ADC technology and corresponding scientific posters can be found here.

  • Gallo F, Korsak B, Müller C, Hechler T, Yanakieva D, Avrutina O, Kolmar H, Pahl A.
  • Enhancing the Pharmacokinetics and Antitumor Activity of an α-Amanitin-Based Small-Molecule Drug Conjugate via Conjugation with an Fc Domain.
  • In: J Med Chem. 2021 Apr 8;64(7):4117-4129. (DOI: 10.1021/acs.jmedchem.1c00003). Epub 2021 Mar 23. (PMID: 33755471).
  •  
  • Li Y, Sun Y, Kulke M, Hechler T, Van der Jeught K, Dong T, He B, Miller KD, Radovich M, Schneider BP, Pahl A, Zhang X, Lu X.
  • Targeted immunotherapy for HER2-low breast cancer with 17p loss.
  • In: Sci Transl Med. 2021 Feb 10;13(580):eabc6894. (DOI: 10.1126/scitranslmed.abc6894; PMID: 33568521).
  •  
  • Figueroa-Vazquez V, Ko J, Breunig C, Baumann A, Giesen N, Pálfi A, Müller C, Lutz C, Hechler T, Kulke M, Müller-Tidow C, Krämer A, Goldschmidt H, Pahl A, Raab MS.
  • HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells.
  • In:  Mol Cancer Ther. 2021 Feb;20(2):367-378. (DOI: 10.1158/1535-7163.MCT-20-0287). Epub 2020 Dec 9. (PMID: 33298585).
  •  
  • Ramkumar P, Abarientos AB, Tian R, Seyler M, Leong JT, Chen M, Choudhry P, Hechler T, Shah N, Wong SW, Martin TG, Wolf JL, Roybal KT, Pahl A, Taunton J, Wiita AP, Kampmann M.
  • CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.
  • In: Blood Adv. 2020 Jul 14;4(13):2899-2911. (DOI: 10.1182/bloodadvances.2019001346; PMID: 32589729; PMCID: PMC7362346)
  •  
  • Lutz C, Simon W, Werner-Simon S, Pahl A, Müller C.
  • Total Synthesis of α- and β-Amanitin.
  • In: Angew Chem Int Ed Engl. 2020 Jul 6;59(28):11390-11393. (DOI: 10.1002/anie.201914935). Epub 2020 Apr 28. (PMID: 32091645)
  • Pahl A, Lutz C, Hechler T
  • Amatoxins as RNA Polymerase II Inhibiting Antibody–Drug Conjugate (ADC) Payloads
  • In: Cytotoxic Payloads for Antibody–Drug Conjugates, CHAPTER 19, The Royal Society of Chemistry 2019
  • ISBN: 978-1-78801-077-1 (DOI: 10.1039/9781788012898-00398)
  •  
  • Pahl A, Lutz C, Hechler T
  • Amanitins and their development as a payload for antibody-drug conjugates
  • In: Drug Discovery Today: Technologies (DOI: 10.1016/j.ddtec.2018.08.005)
  •  
  • Bodero L, López Rivas P, Korsak B, Hechler T, Pahl A, Müller C, Arosio D, Pignataro L, Gennari C, Piarulli U.
  • Synthesis and biological evaluation of RGD and isoDGR peptidomimetic-α-amanitin conjugates for tumor-targeting
  • In: Beilstein J. Org. Chem. 2018, 14, 407–415. (DOI: 10.3762/bjoc.14.29)
  •  
  • Hechler T, Kulke M, Anderl J.
    New drugs and optimization of drug potency. (DOI: 10.4155/fseb2013.14.44)
    In: Optimizing Antibody-Drug Conjugates for Targeted Delivery of Therapeutics.
    Future Science: 2015, Pages 22-38 (DOI: 10.4155/9781910419359)
  •  
  • Liu Y, Zhang X, Han C, Wan G, Huang X, Ivan C, Jiang D, Rodriguez-Aguayo C, Lopez-Berestein G, Rao PH, Maru DM, Pahl A, He X, Sood AK, Ellis LM, Anderl J, Lu X.
    TP53 loss creates therapeutic vulnerability in colorectal cancer.
    Nature. 2015 Apr 30;520(7549):697-701. (PMID: 25901683)
  •  
  • Moldenhauer G, Salnikov AV, Lüttgau S, Herr I, Anderl J, Faulstich H.
    Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
    J Natl Cancer Inst. 2012 Apr 18;104(8):622-34. (PMID: 22457476)
  •  
  • Anderl J, Faulstich H, Hechler T, Kulke M.
    Antibody-drug conjugate payloads.
    Methods Mol Biol. 2013;1045:51-70. (PMID: 23913141)
  •  
  • Voss C, Schmitt B, Werner-Simon S, Lutz C, Simon W, Anderl J.
    A novel, non-radioactive eukaryotic in vitro transcription assay for sensitive quantification of RNA polymerase II activity.
    BMC Mol Biol. 2014 Apr 3;15(1):7 (PMID: 24694320)

Animal Models

  • Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, Vogel V, Klaus B, Nadler W, Rösli C, Lutz C, Kulke M, Engelhardt J, Zickgraf FM, Espinosa O, Schlesner M, Jiang X, Kopp-Schneider A, Neuhaus P, Bahra M, Sinn BV, Eils R, Giese NA, Hackert T, Strobel O, Werner J, Büchler MW, Weichert W, Trumpp A, Sprick MR.
    CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.
    Nat Med. 2016 Feb 8;. (PMID: 26855150)
  •  
  • Grill JI, Neumann J, Hiltwein F, Kolligs FT, Schneider MR.
    Intestinal E-cadherin Deficiency Aggravates Dextran Sodium Sulfate-Induced Colitis.
    Dig Dis Sci. 2015 Apr;60(4):895-902. (PMID: 25634675)
  •  
  • Sann H, Erichsen JV, Hessmann M, Pahl A, Hoffmeyer A.
    Efficacy of drugs used in the treatment of IBD and combinations thereof in acute DSS-induced colitis in mice.
    Life Sci. 2013 Apr 9;92(12):708-18. (PMID: 23399699)
  •  
  • Schuh K, Pahl A.
    Inhibition of the MAP kinase ERK protects from lipopolysaccharide-induced lung injury.
    Biochem Pharmacol. 2009 Jun 15;77(12):1827-34. (PMID: 19428337)
  •  
  • Pahl A.
    Preclinical modelling using nasal epithelial cells for the evaluation of herbal extracts for the treatment of upper airway diseases.
    Planta Med. 2008 May;74(6):693-6. (PMID: 18186014)
  •  
  • Puljic R, Benediktus E, Plater-Zyberk C, Baeuerle PA, Szelenyi S, Brune K, Pahl A.
    Lipopolysaccharide-induced lung inflammation is inhibited by neutralization of GM-CSF.
    Eur J Pharmacol. 2007 Feb 28;557(2-3):230-5. (PMID: 17174948)
  •  
  • Chialda L, Zhang M, Brune K, Pahl A.
    Inhibitors of mitogen-activated protein kinases differentially regulate costimulated T cell cytokine production and mouse airway eosinophilia.
    Respir Res. 2005 Apr 15;6:36. (PMID: 15833106)
  •  
  • Pahl A, Zhang M, Török K, Kuss H, Friedrich U, Magyar Z, Szekely J, Horvath K, Brune K, Szelenyi I.
    Anti-inflammatory effects of a cyclosporine receptor-binding compound, D-43787.
    J Pharmacol Exp Ther. 2002 May;301(2):738-46. (PMID: 11961080)

Bioanalytics

  • Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, Vogel V, Klaus B, Nadler W, Rösli C, Lutz C, Kulke M, Engelhardt J, Zickgraf FM, Espinosa O, Schlesner M, Jiang X, Kopp-Schneider A, Neuhaus P, Bahra M, Sinn BV, Eils R, Giese NA, Hackert T, Strobel O, Werner J, Büchler MW, Weichert W, Trumpp A, Sprick MR.
    CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.
    Nat Med. 2016 Feb 8;. (PMID: 26855150)
  •  
  • Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, Schumacher T, Jestaedt L, Schrenk D, Weller M, Jugold M, Guillemin GJ, Miller CL, Lutz C, Radlwimmer B, Lehmann I, von Deimling A, Wick W, Platten M.
    An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor.
    Nature. 2011 Oct 5;478(7368):197-203. (PMID: 21976023)
  •  
  • Opitz CA, Litzenburger UM, Opitz U, Sahm F, Ochs K, Lutz C, Wick W, Platten M.
    The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells.
    PLoS One. 2011;6(5):e19823 (PMID: 21625531)

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.